Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor.

The crystal structures of ligand-free and agonist-associated ligand-binding domain (LBD) of nuclear receptors (NRs) reveal that the amphipathic helix H12 is folded back toward the LBD core in the agonist-associated conformation, allowing the binding of coactivators. We used alanine scanning mutagenesis to explore the role of the residues of the loop connecting H11 and H12 in the activation of the human mineralocorticoid receptor (hMR), a member of the NRs family. H950A retained the ligand binding and transcriptional activities of the wild-type receptor and interacted with coactivators. In contrast F956A had no receptor functions. Aldosterone bound to the mutant hMRs (L952A, K953A, V954A, E955A, P957A) with nearly the same affinity as to the wild-type receptor and caused a receptor conformational change in these mutant hMRs as it does for the wild-type receptor. But the aldosterone-induced transcriptional activity of the mutant hMRs was lower (L952A, E955A, P957A) than that of the wild-type receptor or completely abolished (K953A, V954A) and their interaction with coactivators was impaired (E955A) or suppressed (L952A, K953A, V954A, P957A). In the light of a hMR-LBD model based on the structure of the progesterone-associated receptor-LBD, we propose that the integrity of the H11-H12 loop is crucial for folding the receptor into a ligand-binding competent state and for establishing the network of contacts that stabilize the active receptor conformation.

[1]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[2]  William Bourguet,et al.  A canonical structure for the ligand-binding domain of nuclear receptors , 1996, Nature Structural Biology.

[3]  K. Wood,et al.  Firefly luciferase gene: structure and expression in mammalian cells , 1987, Molecular and cellular biology.

[4]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[5]  M. Garabedian,et al.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.

[6]  H. Gronemeyer,et al.  The nuclear receptor ligand-binding domain: structure and function. , 1998, Current opinion in cell biology.

[7]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[8]  C. Glass,et al.  Co-activators and co-repressors in the integration of transcriptional responses. , 1998, Current opinion in cell biology.

[9]  M. Stallcup,et al.  Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. , 1998, Molecular Endocrinology.

[10]  M. Lombès,et al.  Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. , 1996, The Biochemical journal.

[11]  E. Kalkhoven,et al.  AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.

[12]  G J Kleywegt,et al.  Detection, delineation, measurement and display of cavities in macromolecular structures. , 1994, Acta crystallographica. Section D, Biological crystallography.

[13]  S V Evans,et al.  SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. , 1993, Journal of molecular graphics.

[14]  P. Sigler,et al.  Atomic structure of progesterone complexed with its receptor , 1998, Nature.

[15]  G. Long,et al.  A general method of site-specific mutagenesis using a modification of the Thermus aquaticus polymerase chain reaction. , 1989, Analytical biochemistry.

[16]  D. Moras,et al.  Antagonism in the human mineralocorticoid receptor , 1998, The EMBO journal.

[17]  P. Kushner,et al.  Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.

[18]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[19]  P B Sigler,et al.  Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Nicolas,et al.  RIP 140 enhances nuclear receptor-dependent transcription in vivo in yeast. , 1997, Molecular endocrinology.

[21]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[22]  A. Venot,et al.  Statistical test of models and computerised parameter estimation for aldosterone binding in rat kidney , 1978 .

[23]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[24]  R. Fletterick,et al.  X-ray crystallographic and functional studies of thyroid hormone receptor 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  J. Fagart,et al.  The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. , 1995, Endocrinology.

[26]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[27]  G. Jenster,et al.  Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. , 1997, Recent progress in hormone research.

[28]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[29]  J. Nicolas,et al.  Conformational Change in the Human Glucocorticoid Receptor Induced by Ligand Binding Is Altered by Mutation of Isoleucine 747 by a Threonine* , 1999, The Journal of Biological Chemistry.

[30]  G J Barton,et al.  ALSCRIPT: a tool to format multiple sequence alignments. , 1993, Protein engineering.

[31]  F. Holsboer,et al.  Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. , 1995, Biochemical and biophysical research communications.

[32]  E. Baulieu,et al.  Mineralocorticosteroid receptor of the chick intestine. Oligomeric structure and transformation. , 1989, The Journal of biological chemistry.

[33]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[34]  R. Fletterick,et al.  A natural transactivation mutation in the thyroid hormone beta receptor: impaired interaction with putative transcriptional mediators. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  W. Pratt,et al.  Steroid receptor interactions with heat shock protein and immunophilin chaperones. , 1997, Endocrine reviews.

[36]  E. Kalkhoven,et al.  Isoforms of steroid receptor co‐activator 1 differ in their ability to potentiate transcription by the oestrogen receptor , 1998, The EMBO journal.

[37]  Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor. , 1998, Molecular endocrinology.

[38]  M. Yaniv,et al.  Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma , 1984, Cell.

[39]  P. Chambon,et al.  The N‐terminal part of TIF1, a putative mediator of the ligand‐dependent activation function (AF‐2) of nuclear receptors, is fused to B‐raf in the oncogenic protein T18. , 1995, The EMBO journal.

[40]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[41]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[42]  R. St-Arnaud,et al.  Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. , 1997, Molecular endocrinology.

[43]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[44]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[45]  M. Parker,et al.  Interaction of proteins with transcriptionally active estrogen receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Richard-Foy,et al.  Cooperation between structural elements in hormono-regulated transcription from the mouse mammary tumor virus promoter. , 1991, Nucleic acids research.

[47]  F. S. French,et al.  Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. , 1995, Molecular endocrinology.

[48]  J D Baxter,et al.  The nuclear hormone receptor gene superfamily. , 1995, Annual review of medicine.

[49]  F. Kaye,et al.  Identification of cellular proteins that can interact specifically with the T/ElA-binding region of the retinoblastoma gene product , 1991, Cell.

[50]  Jean-Paul Renaud,et al.  Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.

[51]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[52]  H. Rochefort,et al.  Differential Interaction of Nuclear Receptors with the Putative Human Transcriptional Coactivator hTIF1* , 1997, The Journal of Biological Chemistry.